Nasus Pharma Ltd. (NSRX) News
Follow Nasus Pharma Ltd. (NSRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. NYSE:NSRX (“Nasus Pharma” or the “Company”), a clinic
GEOPOLITICS | Sep 29, 2026, 12:09 PM UTC
L
Nasus Pharma to participate in H.C. Wainwright 28th conference
Nasus Pharma (NSRX) says it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 08, 2026, 11:30 AM UTC
M
Nasus Pharma announces chief financial officer transition
Nasus Pharma says it is transitioning its chief financial officer role, with no further details on timing or replacement provided in the alert.
EQUITY | Aug 19, 2026, 11:00 AM UTC
H
Nasus Pharma (NSRX) reports First Half 2026 results, gives business update
Nasus Pharma (NSRX) reports its First Half 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EQUITY | Aug 17, 2026, 12:14 PM UTC
L
NSRX - Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth - Click
NSRX - Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
EQUITY | Jul 28, 2026, 11:30 AM UTC
L
NSRX: CEO Buys 6,550 Shares
Nasus Pharma CEO Dan Benjamin Teleman buys 6,550 shares at $3.1
EQUITY | Jun 22, 2026, 11:21 AM UTC